Lu Si, MD
Department of Kidney Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China
Dr. Lu Si specializes in melanoma cancer and renal cancer as a dupty chief physician at Peking University Cancer hospital and Associated professor at Clinical oncology school of Peking University. She serves on the faculty in this hospital from 2004 after she recieved her MD. degree from Xi'an Jiaotong University.
Dr. Lu Si's research is dedicated to finding novel therapies and improving the effectiveness current therapies for melanoma, while continuing to understand the basic mechanisms of the disease and its therapies. Dr. Lu Si has many publications in the field of melanoma including J Clin Oncol, Clin Can Res, E J Can and So on. She led on many occasions, local teams of investigators, and published the first report on the effecitve role of the novel agent imatinib in the treatment and the role of adjuvant therapy of primary acral and mucosal melanoma. One of Dr. Lu Si key interests is developing therapeutic strategies that help overcome resistance to imatinib. Dr. Lu Si serves as the secratory of the Asia Melanoma Group and the Melanoma Committee of Chinese Society of Clinical Oncology. Dr. Lu Si who has lectured nationwide on the subject on melanomas, is also a strong advocate for raising awareness and support for improving the outcome of patients with this disease, and enhancing oncologic education nationwide.